Abstract
In order to create safe and efficacious vaccines, formulations that confer stability must generally be developed. In this chapter, formulation considerations consisting of solution conditions, particles, delivery route, endotoxin level, and preservatives will be covered along with the addition of adjuvants currently approved for use in vaccines and adjuvants currently being researched. Methods to increase vaccine stability and analytical techniques used to monitor vaccines will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams MM et al (2010) Design and synthesis of potent Quillaja saponin vaccine adjuvants. J Am Chem Soc 132(6):1939–1945
Akers MJ, Vasudevan V, Stickelmeyer M (2002) Formulation development of protein dosage forms. In: Nail SL, Akers MJ (eds) Development and manufacture of protein pharmaceuticals. Kluwer Academic/Plenum Publishers, New York, pp 47–127
Amorij JP et al (2008) Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 25(6):1256–1273
Aucouturier J et al (2002) Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1(1):111–118
Aucouturier J, Ascarateil S, Dupuis L (2006) The use of oil adjuvants in therapeutic vaccines. Vaccine 24:S44–S45
Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11):787–796
Bal SM et al (2010) Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 148(3):266–282
Baldridge JR et al (2004) Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4(7):1129–1138
Bee JS et al (2009) Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. J Pharm Sci 98(9):3218–3238
Berthold I et al (2005) Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 23(16):1993–1999
Boland G et al (2004) Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23(3):316–320
Bowey K, Neufeld RJ (2010) Systemic and mucosal delivery of drugs within polymeric microparticles produced by spray drying. BioDrugs 24(6):359–377
Brandau DT et al (2003) Thermal stability of vaccines. J Pharm Sci 92(2):218–231
Braun LJ et al (2009) Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 27(1):72–79
Brazeau GA et al (1998) Current perspectives on pain upon injection of drugs. J Pharm Sci 87(6):667–677
Brito LA, Singh M (2011) Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci 100(1):34–37
Burger JL et al (2008) Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 21(1):25–34
Carpenter JF et al (1997) Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 14(8):969–975
Casella CR, Mitchell TC (2008) Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 65(20):3231–3240
Chang BS, Hershenson S (2002) Practical approaches to protein formulation development. Pharm Biotechnol 13:1–25
Chang M et al (2001) Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine 19(20–22):2884–2889
Clapp T et al (2011) Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci 100(2):388–401
Clausi A et al (2008a) Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci 97(12):5252–5262
Clausi AL et al (2008b) Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J Pharm Sci 97(6):2049–2061
Clausi AL et al (2009) Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine. J Pharm Sci 98(1):114–121
Cleland JL et al (1996) Isomerization and formulation stability of the vaccine adjuvant QS-21. J Pharm Sci 85(1):22–28
Cooper CL et al (2005) CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19(14):1473–1479
Corradin G, Giudice Giuseppe D (2005) Novel adjuvants for vaccines. Curr Med Chem Anti Inflamm Anti Allergy Agents 4(2):185–191
Davis SS (2001) Nasal vaccines. Adv Drug Deliv Rev 51(1–3):21–42
Descamps D et al (2009) Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 5(5):332–340
Devriendt B et al (2012) Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery. J Control Release 160(3):431–439
Diminsky D et al (1999) Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18(1–2):3–17
Dong A et al (2006) Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations. Anal Biochem 351(2):282–289
Egan PM et al (2009) Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-adsorbed hepatitis B vaccine. Vaccine 27(24):3175–3180
Evans TG et al (2001) QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19(15–16):2080–2091
FDA (2012a) Vaccines licensed for immunization and distribution in the US with supporting documents. Available from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093830.htm
FDA (2012b) Thimerosal in vaccines. [Online]. Available from http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/UCM096209
Fradkin AH, Carpenter JF, Randolph TW (2011) Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100(11):4953–4964
Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4(4):298–306
Garcon N, Chomez P, Van Mechelen M (2007) GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6(5):723–739
Geier DA, Jordan SK, Geier MR (2010) The relative toxicity of compounds used as preservatives in vaccines and biologics. Med Sci Monit 16(5):SR21–SR27
Gnjatic S, Sawhney NB, Bhardwaj N (2010) Toll-like receptor agonists—are they good adjuvants? Cancer J 16(4):382–391
Gorbet MB, Sefton MV (2005) Endotoxin: the uninvited guest. Biomaterials 26(34):6811–6817
Hansen B et al (2011) Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum-containing adjuvants on the immune response. J Pharm Sci 100(8):3245–3250
Helling F et al (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55(13):2783–2788
Hem SL et al (2010) Preformulation studies—the next advance in aluminum adjuvant-containing vaccines. Vaccine 28(31):4868–4870
Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11(4 suppl):S45–S53
Kamerzell TJ et al (2011) Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63(13):1118–1159
Kamstrup S et al (2000) Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A. Vaccine 18(21):2244–2249
Kanchan V, Panda AK (2007) Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28(35):5344–5357
Kensil CR, Kammer R (1998) QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 7(9):1475–1482
Kensil CR et al (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146(2):431–437
LiCalsi C et al (2001) A powder formulation of measles vaccine for aerosol delivery. Vaccine 19(17–19):2629–2636
Lopez JA et al (2001) A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans: implications for vaccination strategies. Eur J Immunol 31(7):1989–1998
Lycke N (2004) From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol 6(1):23–32
Maddux NR et al (2011) Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100(10):4171–4197
Magalhaes PO et al (2007) Methods of endotoxin removal from biological preparations: a review. J Pharm Sci 10(3):388–404
Malyala P, Singh M (2008) Endotoxin limits in formulations for preclinical research. J Pharm Sci 97(6):2041–2044
Manning MC, Patel K, Borchardt RT (1989) Stability of protein pharmaceuticals. Pharm Res 6(11):903–918
Mbawuike I, Zang Y, Couch RB (2007) Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine 25(17):3263–3269
Mbow ML et al (2010) New adjuvants for human vaccines. Curr Opin Immunol 22(3):411–416
McKenzie A, Watt M, Gittleson C (2010) ISCOMATRIX vaccines—safety in human clinical studies. Hum Vaccin 6(3):237–246
Morel S et al (2011) Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13):2461–2473
Moser C, Amacker M, Zurbriggen R (2011) Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 10(4):437–446
Naylor PH et al (2010) IRX-2 increases the T cell-specific immune response to protein/peptide vaccines. Vaccine 28(43):7054–7062
Nechansky A, Kircheis R (2010) Immunogenicity of therapeutics: a matter of efficacy and safety. Expert Opin Drug Discov 5(11):1067–1079
Noe SM et al (2010) Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 28(20):3588–3594
O’Hagan DT, De Gregorio E (2009) The path to a successful vaccine adjuvant—‘The long and winding road’. Drug Discov Today 14(11–12):541–551
O’Hagan DT, Ott GS, Van Nest G (1997) Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 3(2):69–75
O’Hagan DT et al (2011) MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 10(4):447–462
Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9(9):1095–1107
Pearse MJ, Drane D (2005) ISCOMATRIX(R) adjuvant for antigen delivery. Adv Drug Deliv Rev 57:465–474
Peek LJ et al (2007) Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci 96(3):547–557
Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12(6):509–517
Rappuoli R et al (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11(12):865–872
Reed SG et al (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30(1):23–32
Roestenberg M et al (2008) Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3(12):e3960
Romero Mendez IZ et al (2007) Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 25(5):825–833
Rowe RC, Sheskey PJ, Quinn ME (2009) Handbook of pharmaceutical excipients. Pharmaceutical Press, London
Russell-Jones GJ (2000) Oral vaccine delivery. J Control Release 65(1–2):49–54
Schultze V et al (2008) Safety of MF59 adjuvant. Vaccine 26(26):3209–3222
Seeber SJ, White JL, Hem SL (1991) Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 9(3):201–203
Shire SJ, Shahrokh Z, Liu J (2004) Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390–1402
Singh M et al (2006) A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24(10):1680–1686
Sou T et al (2011) New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol 29(4):191–198
Steinhagen F et al (2011) TLR-based immune adjuvants. Vaccine 29(17):3341–3355
Stolnik S, Shakesheff K (2009) Formulations for delivery of therapeutic proteins. Biotechnol Lett 31(1):1–11
Stoute JA et al (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 336(2):86–91
Sun H-X, Xie Y, Ye Y-P (2009) ISCOMs and ISCOMATRIX. Vaccine 27:4388–4401
Titkov ES, Oganesian GA (1995) The chronic action of large doses of aluminum on nervous and cardiac activities in rats administered it intramuscularly. Zh Evol Biokhim Fiziol 31(1):52–58
Vajdy M et al (2004) Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 82(6):617–627
Vecchi S et al (2012) Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. J Pharm Sci 101(1):17–20
Vessely C et al (2009) Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci 98(9):2970–2993
Vogel FR (2000) Improving vaccine performance with adjuvants. Clin Infect Dis 30(suppl 3):S266–S270
Volkin DB et al (2002) Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals. Pharm Biotechnol 14:1–46
Wang W et al (2007) Antibody structure, instability, and formulation. J Pharm Sci 96(1):1–26
WHO (1977) Manual for the production and control of vaccines—tetanus toxoid. BLG/UNDP/77.2 Rev. 1
WHO, UNICEF, World Bank (2009) State of world’s vaccines and immunization, 3rd edn. World Health Organization, Geneva
Wilson-Welder JH et al (2009) Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 98(4):1278–1316
Worrall EE et al (2001) Xerovac: an ultra rapid method for the dehydration and preservation of live attenuated Rinderpest and Peste des Petits ruminants vaccines. Vaccine 19(28–29):834–839
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Hassett, K.J., Nandi, P., Randolph, T.W. (2013). Formulation Approaches and Strategies for Vaccines and Adjuvants. In: Kolhe, P., Shah, M., Rathore, N. (eds) Sterile Product Development. AAPS Advances in the Pharmaceutical Sciences Series, vol 6. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7978-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7978-9_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7977-2
Online ISBN: 978-1-4614-7978-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)